SG11201906959RA - Aryl hydrocarbon receptor (ahr) modulator compounds - Google Patents
Aryl hydrocarbon receptor (ahr) modulator compoundsInfo
- Publication number
- SG11201906959RA SG11201906959RA SG11201906959RA SG11201906959RA SG11201906959RA SG 11201906959R A SG11201906959R A SG 11201906959RA SG 11201906959R A SG11201906959R A SG 11201906959RA SG 11201906959R A SG11201906959R A SG 11201906959RA SG 11201906959R A SG11201906959R A SG 11201906959RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ahr
- compounds
- aryl hydrocarbon
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000157 | 2017-02-01 | ||
| PCT/EP2018/052538 WO2018141855A1 (fr) | 2017-02-01 | 2018-02-01 | Composés modulateurs du récepteur des hydrocarbures d'aryl (ahr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906959RA true SG11201906959RA (en) | 2019-08-27 |
Family
ID=57960222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906959RA SG11201906959RA (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11376241B2 (fr) |
| EP (1) | EP3577115B1 (fr) |
| JP (1) | JP2020505467A (fr) |
| KR (1) | KR20190113902A (fr) |
| CN (1) | CN110234650A (fr) |
| AR (1) | AR110790A1 (fr) |
| AU (1) | AU2018216955B2 (fr) |
| BR (1) | BR112019015704A2 (fr) |
| CA (1) | CA3051034A1 (fr) |
| CL (1) | CL2019002112A1 (fr) |
| CO (1) | CO2019007882A2 (fr) |
| CR (1) | CR20190393A (fr) |
| CU (1) | CU20190067A7 (fr) |
| EA (1) | EA201991600A1 (fr) |
| EC (1) | ECSP19055179A (fr) |
| IL (1) | IL268082A (fr) |
| MX (1) | MX2019008993A (fr) |
| NI (1) | NI201900075A (fr) |
| PE (1) | PE20191479A1 (fr) |
| PH (1) | PH12019550136A1 (fr) |
| SG (1) | SG11201906959RA (fr) |
| TW (1) | TWI674260B (fr) |
| UA (1) | UA122746C2 (fr) |
| UY (1) | UY37590A (fr) |
| WO (1) | WO2018141855A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| US10815250B2 (en) | 2018-02-06 | 2020-10-27 | Ideaya Biosciences, Inc. | AhR modulators |
| WO2020021024A1 (fr) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| US20220281824A1 (en) * | 2019-07-30 | 2022-09-08 | Oregon State University | Aryl hydrocarbon receptor activators |
| KR102351515B1 (ko) * | 2019-12-17 | 2022-01-14 | (주)수파드엘릭사 | 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
| EP4093739A1 (fr) * | 2020-01-23 | 2022-11-30 | Phenex Pharmaceuticals AG | Composés hétérocycliques substitués par un oxalamide en tant que modulateurs du récepteur d'aryle hydrocarbone (ahr) |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| JP2024500989A (ja) * | 2020-12-28 | 2024-01-10 | セルジーン コーポレーション | 寄生虫症のためのヘテロ環化合物およびそれらの使用 |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8225991A (en) | 1990-07-31 | 1992-03-02 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
| CA2271767A1 (fr) | 1996-11-19 | 1998-05-28 | Nathan B. Mantlo | Agents anti-inflammatoires a base de pyrrole condense a substitution aryle et heteroaryle |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2009515926A (ja) | 2005-11-18 | 2009-04-16 | エフ．ホフマン−ラ ロシュ アーゲー | アザインドール−２−カルボキサミド誘導体 |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| PT2488486T (pt) | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
| US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| US8604067B2 (en) * | 2009-11-02 | 2013-12-10 | Ahr Pharmaceuticals, Inc. | ITE for cancer intervention and eradication |
| SI2531501T1 (sl) * | 2010-02-03 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Inhibitorji kinaze-1, ki regulirajo signal apoptoze |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| US10314810B2 (en) | 2010-07-27 | 2019-06-11 | Trustees Of Boston University | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| MX2015004500A (es) | 2012-10-17 | 2015-07-06 | Hoffmann La Roche | Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp). |
| BR112015014752B1 (pt) | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-25 TW TW107102716A patent/TWI674260B/zh not_active IP Right Cessation
- 2018-01-31 AR ARP180100228A patent/AR110790A1/es unknown
- 2018-01-31 UY UY0001037590A patent/UY37590A/es unknown
- 2018-02-01 BR BR112019015704A patent/BR112019015704A2/pt not_active Application Discontinuation
- 2018-02-01 AU AU2018216955A patent/AU2018216955B2/en not_active Ceased
- 2018-02-01 CN CN201880009290.2A patent/CN110234650A/zh not_active Withdrawn
- 2018-02-01 KR KR1020197025765A patent/KR20190113902A/ko not_active Application Discontinuation
- 2018-02-01 EA EA201991600A patent/EA201991600A1/ru unknown
- 2018-02-01 PE PE2019001483A patent/PE20191479A1/es unknown
- 2018-02-01 SG SG11201906959RA patent/SG11201906959RA/en unknown
- 2018-02-01 MX MX2019008993A patent/MX2019008993A/es unknown
- 2018-02-01 JP JP2019561369A patent/JP2020505467A/ja not_active Ceased
- 2018-02-01 CA CA3051034A patent/CA3051034A1/fr not_active Withdrawn
- 2018-02-01 UA UAA201908355A patent/UA122746C2/uk unknown
- 2018-02-01 US US16/479,847 patent/US11376241B2/en active Active
- 2018-02-01 CR CR20190393A patent/CR20190393A/es unknown
- 2018-02-01 CU CU2019000067A patent/CU20190067A7/es unknown
- 2018-02-01 WO PCT/EP2018/052538 patent/WO2018141855A1/fr unknown
- 2018-02-01 EP EP18707242.6A patent/EP3577115B1/fr active Active
-
2019
- 2019-07-15 IL IL268082A patent/IL268082A/en unknown
- 2019-07-15 NI NI201900075A patent/NI201900075A/es unknown
- 2019-07-23 CO CONC2019/0007882A patent/CO2019007882A2/es unknown
- 2019-07-24 PH PH12019550136A patent/PH12019550136A1/en unknown
- 2019-07-29 CL CL2019002112A patent/CL2019002112A1/es unknown
- 2019-07-31 EC ECSENADI201955179A patent/ECSP19055179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20190067A7 (es) | 2020-03-04 |
| UY37590A (es) | 2018-02-28 |
| ECSP19055179A (es) | 2019-08-30 |
| AU2018216955A1 (en) | 2019-08-01 |
| JP2020505467A (ja) | 2020-02-20 |
| EP3577115A1 (fr) | 2019-12-11 |
| IL268082A (en) | 2019-09-26 |
| KR20190113902A (ko) | 2019-10-08 |
| UA122746C2 (uk) | 2020-12-28 |
| EP3577115B1 (fr) | 2020-12-02 |
| CN110234650A (zh) | 2019-09-13 |
| WO2018141855A1 (fr) | 2018-08-09 |
| NI201900075A (es) | 2019-10-30 |
| BR112019015704A2 (pt) | 2020-04-07 |
| CR20190393A (es) | 2019-10-21 |
| US20210260045A1 (en) | 2021-08-26 |
| CO2019007882A2 (es) | 2019-10-09 |
| CA3051034A1 (fr) | 2018-08-09 |
| AR110790A1 (es) | 2019-05-02 |
| EA201991600A1 (ru) | 2020-03-10 |
| TWI674260B (zh) | 2019-10-11 |
| TW201838991A (zh) | 2018-11-01 |
| US11376241B2 (en) | 2022-07-05 |
| CL2019002112A1 (es) | 2019-12-20 |
| AU2018216955B2 (en) | 2020-09-17 |
| PH12019550136A1 (en) | 2020-03-02 |
| PE20191479A1 (es) | 2019-10-16 |
| MX2019008993A (es) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201903327PA (en) | Crystalline forms of eravacycline | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration |